Clinical Trials Logo

Keratoconjunctivitis Sicca clinical trials

View clinical trials related to Keratoconjunctivitis Sicca.

Filter by:

NCT ID: NCT05629364 Not yet recruiting - Dry Eye Disease Clinical Trials

A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune Disease

Start date: February 2023
Phase: Phase 2
Study type: Interventional

A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, versus Vehicle Control in the treatment of Dry Eye Disease in Patients with Autoimmune Disease

NCT ID: NCT05618730 Recruiting - Dry Eye Clinical Trials

Safety, Tolerability and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B

Start date: September 29, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this interventional study is to assess safety, patient tolerability, plug retention rate, and preliminary efficacy in improving the symptoms of Dry Eye Disease (DED) of EXP-TC tacrolimus releasing punctal plug. The main questions it aims to answer are: 1. The safety of using EXP-TC plug following all study adverse events 2. The number of patients with Adverse Events related to the us of EXP-LP plug 3. The number of patients discontinuing the study due to plug discomfort 4. The total patients with plugs remained during the 3-months study duration from plug insertion 5. Exploratory: change from baseline in the study eye to follow-up visits in various Dryness clinical measurements. The change of measurements from baseline will also be compared between the study and fellow control eye (receiving artificial tears only, 0.15% sodium hyaluronate).

NCT ID: NCT05605314 Recruiting - Dry Eye Clinical Trials

Clinical Cohort Study in Patients With Different Subtypes of Primary Sjogren Syndrome Related Dry Eye

pSS
Start date: January 1, 2021
Phase:
Study type: Observational

Primary Sjögren's syndrome is a chronic autoimmune disease that primarily involves exocrine glands, most commonly manifested in dry eye, dry mouth, and in other systems of the body.

NCT ID: NCT05604651 Completed - Dry Eye Disease Clinical Trials

Comparison of Mucin Levels at the Ocular Surface of Visual Display Users With and Without Dry Eye Disease

Start date: March 1, 2021
Phase:
Study type: Observational

The study aimed to evaluate 1) if levels of the glycocalyx membrane mucins, including MUC1, MUC4, MUC16 and MUC20, are altered in conjunctival cells of visual display users With and Without Dry Eye Disease, and 2) if mucin levels correlate with dry eye clinical diagnostic data.

NCT ID: NCT05600985 Not yet recruiting - Dry Eye Clinical Trials

Clinical Characteristics of Patients Developing Chronic Dry Eye After Refractive Surgery

Start date: October 31, 2022
Phase:
Study type: Observational

In recent years, many scholars have studied the ocular surface damage of patients with dry eye disease(DED)after FS-LASIK, but there has been a lack of comprehensive observation and research on the relationship and difference between dry eye (DE)patients with and without LASIK. Therefore, the purpose of this study was to investigate the characteristics of ocular surface and cytokines after FS-LASIK, and further explain the pathogenesis of chronic dry eyes after FS-LASIK.

NCT ID: NCT05598437 Recruiting - Dry Eye Syndromes Clinical Trials

Prevalence of Different Etiologies of Ocular Dryness in Patients Previously Diagnosed With Dry Eye Disease in A Sample of Egyptian Patients

Start date: November 1, 2022
Phase:
Study type: Observational

Proposed Study Title: Prevalence of Different Etiologies of Ocular Dryness in Patients Previously Diagnosed with Dry Eye

NCT ID: NCT05598242 Completed - Dry Eye Syndromes Clinical Trials

Amniotic Membrane Treatment for Hyposecretory Dry Eye

Start date: February 1, 2019
Phase: Phase 3
Study type: Interventional

The goal of this randomized, active-controlled, parallel-group trial is to evaluate the clinical efficacy of amniotic membrane extract eye drops (AMEED) in reducing signs and symptoms of hyposecretory dry eye Participants will receibed amniotic membrane extract eye drops 6 times daily and was evaluated at baseline day and day 30th. Researchers will compare against autologous serum eye drops effects

NCT ID: NCT05594745 Active, not recruiting - Dry Eye Syndromes Clinical Trials

Treatment Regimens in Meibomian Gland Dysfunction

Start date: March 2, 2021
Phase: Phase 4
Study type: Interventional

This study seeks to explore the relevance of inflammation in dry eye patients with MGD and compare the efficacy of LipiFlow treatment followed by lid hygiene and lubricant treatment with Systane Ultra or LipiFlow treatment followed by lid hygiene and lifitegrast treatment in patients with meibomian gland dysfunction.

NCT ID: NCT05586152 Recruiting - Dry Eye Disease Clinical Trials

Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease

Start date: August 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1/2, first-in-human, 2-part study to assess topically administered eyedrops of INV-102 during 2-week repeat dosing in subjects with moderate symptomatic dry eye disease. Part 1 will be a Dose Escalation phase across 4 cohorts of subjects to assess safety and tolerability of INV-102, and Part 2 will be an Optional Dose Expansion phase in a fifth cohort of subjects, pending the outcome of Part 1, to assess efficacy of INV-102 in the treatment of moderate symptomatic dry eye disease.

NCT ID: NCT05576415 Not yet recruiting - Dry Eye Disease Clinical Trials

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of OC-01 in Adult Chinese With Dry Eye Disease

Start date: November 2022
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate the pharmacokinetics (PK) in adult Chinese subjects with dry eye disease (DED)1 after bilateral nasal spray administration of OC-01 (varenicline solution) Nasal Spray at a concentration of 0.6 mg/mL.